Analysts Set ABIVAX Société Anonyme (NASDAQ:ABVX) Target Price at $36.50

ABIVAX Société Anonyme (NASDAQ:ABVX) has been assigned an average recommendation of “Moderate Buy” from the seven analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $36.50.

Separately, Laidlaw began coverage on ABIVAX Société Anonyme in a research report on Monday, July 29th. They issued a “buy” rating and a $48.00 price target on the stock.

ABIVAX Société Anonyme Trading Down 2.1 %

Shares of NASDAQ:ABVX opened at $10.28 on Thursday. The business’s fifty day moving average price is $11.13 and its two-hundred day moving average price is $12.73. ABIVAX Société Anonyme has a fifty-two week low of $8.32 and a fifty-two week high of $17.02.

Hedge Funds Weigh In On ABIVAX Société Anonyme

A number of institutional investors and hedge funds have recently bought and sold shares of ABVX. BNP Paribas Financial Markets acquired a new position in ABIVAX Société Anonyme in the first quarter worth $81,000. Capstone Investment Advisors LLC boosted its stake in ABIVAX Société Anonyme by 9.0% in the first quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock worth $900,000 after purchasing an additional 5,199 shares in the last quarter. Kennedy Capital Management LLC boosted its stake in ABIVAX Société Anonyme by 35.3% in the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after purchasing an additional 31,331 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in ABIVAX Société Anonyme by 18.2% in the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after purchasing an additional 131,414 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.